{ "id": "exforge", "recordTier": "source_traceable_archive", "editorial": { "reviewedAt": "2026-08-21", "status": "published_traceable_archive" }, "names": { "brand": "Exforge", "generic": "氨氯地平/缬沙坦", "aliases": [ "EXFORGE", "amlodipine and valsartan", "amlodipine/valsartan", "氨氯地平/缬沙坦" ], "marketBrandNames": [], "mainlandChinaTradeNameCue": null }, "identity": { "therapeuticArea": "心血管", "sourceArchiveMarket": "美国当前 EXFORGE 氨氯地平/缬沙坦公开标签（DailyMed SPL v36：2026-02-17 生效/更新，2026-02-18 发布）", "dosageFormClass": "口服薄膜衣片：氨氯地平/缬沙坦 5/160、10/160、5/320、10/320 mg（当前美国标签所列）", "dosageFormClassCode": "oral_solid", "route": "口服", "routeCode": "oral", "historicalApprovalEntry": "2007（当前美国标签所列 Initial U.S. Approval）", "archiveSponsorText": "Novartis Pharmaceuticals Corporation / DailyMed（NLM）当前公开标签档案" }, "matchPolicy": { "contract": "reviewed_name_and_exclusion_cues_v1", "exactMatchNames": [], "excludedProductCues": [ "EXFORGE HCT", "hydrochlorothiazide", "氢氯噻嗪" ], "exclusionPrecedence": "before_name_candidate" }, "productPresentations": [ { "id": "us-exforge-amlodipine-5mg-valsartan-160mg-30-tablet-bottle-ndc-0078-0488-15", "marketCode": "US", "labelVersion": { "zh": "DailyMed SPL v36；2026-02-17 生效/更新，2026-02-18 发布", "en": "DailyMed SPL v36; effective/updated 17 Feb 2026 and published 18 Feb 2026" }, "dosageForm": { "zh": "氨氯地平/缬沙坦口服薄膜衣片", "en": "amlodipine/valsartan oral film-coated tablet" }, "route": { "zh": "口服", "en": "oral" }, "routeCodes": [ "oral" ], "productCode": "NDC 0078-0488-15", "pouchCode": null, "applicationNumber": null, "presentationRole": null, "primaryStrengthBasisCode": "per_tablet", "primaryDisplay": { "zh": "每片：氨氯地平 5 mg + 缬沙坦 160 mg；30 片瓶装", "en": "Per tablet: amlodipine 5 mg + valsartan 160 mg; 30-tablet bottle" }, "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&name=exforge-07.jpg", "visualStatus": "exact_public_label_package_image", "labeledQuantities": [ { "ingredient": { "zh": "氨氯地平", "en": "amlodipine" }, "value": 5, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } }, { "ingredient": { "zh": "缬沙坦", "en": "valsartan" }, "value": 160, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } } ], "concentration": null, "container": { "typeCode": "bottle", "typeLabel": { "zh": "儿童安全瓶装", "en": "child-resistant bottle" }, "fill": null, "countPerPackage": 30, "countUnit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "deliveryDevice": null, "compatibleReusableDevice": null, "listingStatus": { "reviewedAt": "2026-08-21", "currentLabelDisplayed": true, "ndcDirectoryListed": true, "marketAvailability": "not_established", "marketingStartDate": null, "marketingEndDate": null, "purpleBookPresentationStatus": null, "statusConflictRequiresManualReview": false }, "package": { "count": 30, "unit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "physicalClues": { "color": { "zh": "深黄色", "en": "dark yellow" }, "shape": { "zh": "椭圆形、有斜边薄膜衣片", "en": "ovaloid, bevel-edged film-coated tablet" }, "imprint": "NVR / ECE", "scoreStatus": "unscored", "patchAreaCm2": null }, "comparisonNotice": null, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion" }, { "id": "us-exforge-amlodipine-10mg-valsartan-160mg-30-tablet-bottle-ndc-0078-0489-15", "marketCode": "US", "labelVersion": { "zh": "DailyMed SPL v36；2026-02-17 生效/更新，2026-02-18 发布", "en": "DailyMed SPL v36; effective/updated 17 Feb 2026 and published 18 Feb 2026" }, "dosageForm": { "zh": "氨氯地平/缬沙坦口服薄膜衣片", "en": "amlodipine/valsartan oral film-coated tablet" }, "route": { "zh": "口服", "en": "oral" }, "routeCodes": [ "oral" ], "productCode": "NDC 0078-0489-15", "pouchCode": null, "applicationNumber": null, "presentationRole": null, "primaryStrengthBasisCode": "per_tablet", "primaryDisplay": { "zh": "每片：氨氯地平 10 mg + 缬沙坦 160 mg；30 片瓶装", "en": "Per tablet: amlodipine 10 mg + valsartan 160 mg; 30-tablet bottle" }, "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&name=exforge-08.jpg", "visualStatus": "exact_public_label_package_image", "labeledQuantities": [ { "ingredient": { "zh": "氨氯地平", "en": "amlodipine" }, "value": 10, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } }, { "ingredient": { "zh": "缬沙坦", "en": "valsartan" }, "value": 160, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } } ], "concentration": null, "container": { "typeCode": "bottle", "typeLabel": { "zh": "儿童安全瓶装", "en": "child-resistant bottle" }, "fill": null, "countPerPackage": 30, "countUnit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "deliveryDevice": null, "compatibleReusableDevice": null, "listingStatus": { "reviewedAt": "2026-08-21", "currentLabelDisplayed": true, "ndcDirectoryListed": true, "marketAvailability": "not_established", "marketingStartDate": null, "marketingEndDate": null, "purpleBookPresentationStatus": null, "statusConflictRequiresManualReview": false }, "package": { "count": 30, "unit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "physicalClues": { "color": { "zh": "浅黄色", "en": "light yellow" }, "shape": { "zh": "椭圆形、有斜边薄膜衣片", "en": "ovaloid, bevel-edged film-coated tablet" }, "imprint": "NVR / UIC", "scoreStatus": "unscored", "patchAreaCm2": null }, "comparisonNotice": null, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion" }, { "id": "us-exforge-amlodipine-5mg-valsartan-320mg-30-tablet-bottle-ndc-0078-0490-15", "marketCode": "US", "labelVersion": { "zh": "DailyMed SPL v36；2026-02-17 生效/更新，2026-02-18 发布", "en": "DailyMed SPL v36; effective/updated 17 Feb 2026 and published 18 Feb 2026" }, "dosageForm": { "zh": "氨氯地平/缬沙坦口服薄膜衣片", "en": "amlodipine/valsartan oral film-coated tablet" }, "route": { "zh": "口服", "en": "oral" }, "routeCodes": [ "oral" ], "productCode": "NDC 0078-0490-15", "pouchCode": null, "applicationNumber": null, "presentationRole": null, "primaryStrengthBasisCode": "per_tablet", "primaryDisplay": { "zh": "每片：氨氯地平 5 mg + 缬沙坦 320 mg；30 片瓶装", "en": "Per tablet: amlodipine 5 mg + valsartan 320 mg; 30-tablet bottle" }, "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&name=exforge-09.jpg", "visualStatus": "exact_public_label_package_image", "labeledQuantities": [ { "ingredient": { "zh": "氨氯地平", "en": "amlodipine" }, "value": 5, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } }, { "ingredient": { "zh": "缬沙坦", "en": "valsartan" }, "value": 320, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } } ], "concentration": null, "container": { "typeCode": "bottle", "typeLabel": { "zh": "儿童安全瓶装", "en": "child-resistant bottle" }, "fill": null, "countPerPackage": 30, "countUnit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "deliveryDevice": null, "compatibleReusableDevice": null, "listingStatus": { "reviewedAt": "2026-08-21", "currentLabelDisplayed": true, "ndcDirectoryListed": true, "marketAvailability": "not_established", "marketingStartDate": null, "marketingEndDate": null, "purpleBookPresentationStatus": null, "statusConflictRequiresManualReview": false }, "package": { "count": 30, "unit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "physicalClues": { "color": { "zh": "深黄色", "en": "very dark yellow" }, "shape": { "zh": "椭圆形、有斜边薄膜衣片", "en": "ovaloid, bevel-edged film-coated tablet" }, "imprint": "NVR / CSF", "scoreStatus": "unscored", "patchAreaCm2": null }, "comparisonNotice": null, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion" }, { "id": "us-exforge-amlodipine-10mg-valsartan-320mg-30-tablet-bottle-ndc-0078-0491-15", "marketCode": "US", "labelVersion": { "zh": "DailyMed SPL v36；2026-02-17 生效/更新，2026-02-18 发布", "en": "DailyMed SPL v36; effective/updated 17 Feb 2026 and published 18 Feb 2026" }, "dosageForm": { "zh": "氨氯地平/缬沙坦口服薄膜衣片", "en": "amlodipine/valsartan oral film-coated tablet" }, "route": { "zh": "口服", "en": "oral" }, "routeCodes": [ "oral" ], "productCode": "NDC 0078-0491-15", "pouchCode": null, "applicationNumber": null, "presentationRole": null, "primaryStrengthBasisCode": "per_tablet", "primaryDisplay": { "zh": "每片：氨氯地平 10 mg + 缬沙坦 320 mg；30 片瓶装", "en": "Per tablet: amlodipine 10 mg + valsartan 320 mg; 30-tablet bottle" }, "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&name=exforge-10.jpg", "visualStatus": "exact_public_label_package_image", "labeledQuantities": [ { "ingredient": { "zh": "氨氯地平", "en": "amlodipine" }, "value": 10, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } }, { "ingredient": { "zh": "缬沙坦", "en": "valsartan" }, "value": 320, "unit": "mg", "basisCode": "per_tablet", "basisLabel": { "zh": "每片标签量；不是个人片数或调药规则", "en": "labelled amount per tablet; not an individual's tablet count or adjustment rule" } } ], "concentration": null, "container": { "typeCode": "bottle", "typeLabel": { "zh": "儿童安全瓶装", "en": "child-resistant bottle" }, "fill": null, "countPerPackage": 30, "countUnit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "deliveryDevice": null, "compatibleReusableDevice": null, "listingStatus": { "reviewedAt": "2026-08-21", "currentLabelDisplayed": true, "ndcDirectoryListed": true, "marketAvailability": "not_established", "marketingStartDate": null, "marketingEndDate": null, "purpleBookPresentationStatus": null, "statusConflictRequiresManualReview": false }, "package": { "count": 30, "unit": { "zh": "片/瓶", "en": "tablets per bottle" } }, "physicalClues": { "color": { "zh": "深黄色", "en": "dark yellow" }, "shape": { "zh": "椭圆形、有斜边薄膜衣片", "en": "ovaloid, bevel-edged film-coated tablet" }, "imprint": "NVR / LUF", "scoreStatus": "unscored", "patchAreaCm2": null }, "comparisonNotice": null, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion" } ], "comparisonPresentations": [], "appearanceReferences": [], "visualReference": { "presentationId": "us-exforge-amlodipine-5mg-valsartan-160mg-30-tablet-bottle-ndc-0078-0488-15", "status": "historical_public_label_image_not_product_authentication", "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&name=exforge-07.jpg", "alt": "EXFORGE 氨氯地平/缬沙坦在美国 DailyMed 当前标签中的 5 mg/160 mg、NDC 0078-0488-15、30 片装包装面板", "archiveMarket": "美国", "labelVersion": "DailyMed SPL v36（2026-02-17 生效/更新；2026-02-18 发布）", "presentation": "EXFORGE 氨氯地平/缬沙坦薄膜衣片：每片 5 mg/160 mg；NDC 0078-0488-15；30 片装包装面板。", "notice": "此图只对应美国当前标签中的 EXFORGE 5 mg/160 mg、NDC 0078-0488-15、30 片装。它不代表 10/160、5/320、10/320 mg，EXFORGE HCT 三成分片，单方氨氯地平/缬沙坦，其他包装或其他市场；不用于鉴定真伪，也不生成个人片数、加减量、转换或联合方案。", "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" } }, "visualCoverageNote": null, "labelReading": { "coverage": "drug_specific_source_review", "title": { "zh": "EXFORGE 说明书放大阅读：5/160 先是两种成分的每片身份", "en": "EXFORGE label reading: 5/160 first identifies both ingredients in one tablet" }, "summary": { "zh": "本模块以当前美国公开标签为阅读入口，帮助核对 EXFORGE、氨氯地平、缬沙坦、完整双数字、口服薄膜衣片与 NDC。它不决定个人是否需要两种降压成分、每天用几片、能否与其他降压药同用或如何调整。", "en": "This module uses the current U.S. public label to check EXFORGE, amlodipine, valsartan, the complete two-number marking, oral film-coated tablet and NDC. It does not decide whether someone needs both antihypertensive ingredients, a tablet count, co-use with another blood-pressure medicine or an adjustment." }, "checks": [ { "zh": "5/160、10/160、5/320、10/320 mg 都是每片中两种成分的完整标示。不能只看其中一个数字，也不能从数字推导个人每天几片、加减量或把两种单方药自行拼成同一复方。", "en": "5/160, 10/160, 5/320 and 10/320 mg are complete two-ingredient markings per tablet. Do not read only one number, derive a personal tablet count, adjust an amount or self-assemble the fixed combination from two single-ingredient products." }, { "zh": "EXFORGE HCT 另含氢氯噻嗪，是三成分产品；它不是本页的 EXFORGE 双成分片。名称相近、都含氨氯地平或缬沙坦，均不能证明可自行叠加、轮换或替代。", "en": "EXFORGE HCT additionally contains hydrochlorothiazide and is a three-ingredient product; it is not the two-ingredient EXFORGE tablet on this page. Similar names or a shared amlodipine/valsartan ingredient do not establish self-combination, alternation or substitution." }, { "zh": "正在使用其他降压药、利尿剂、含缬沙坦/氯沙坦/厄贝沙坦等产品、止痛药、盐替代品、补充剂或多种药物时，应把实际药盒和完整药单交给药师或医生核对；网页不能把“同类”或“共同成分”变成可否合用的个人结论。", "en": "With another antihypertensive, diuretic, a product containing valsartan/losartan/irbesartan, pain medicine, salt substitute, supplement or multiple medicines, have the actual packs and complete list reviewed by a pharmacist or clinician. A webpage cannot turn a shared class or ingredient into an individual co-use conclusion." }, { "zh": "怀孕/计划妊娠、晕厥、明显头晕、胸痛、呼吸困难、面部或咽喉肿胀等情况需要及时联系当地医生或紧急医疗支持；本页不决定是否自行停用、恢复或改用另一种药。", "en": "Pregnancy/planning pregnancy, fainting, marked dizziness, chest pain, breathing trouble, facial or throat swelling or another acute concern needs timely local clinical or urgent support; this page does not decide self-stopping, restarting or changing to another medicine." } ], "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "scope": "label_literacy_only_no_individual_dosing_or_substitution" }, "mechanismReading": { "title": { "zh": "氨氯地平/缬沙坦怎样起作用：标签描述两条不同的降压药理路径", "en": "How amlodipine/valsartan works: the label describes two different antihypertensive pathways" }, "summary": { "zh": "当前标签将 EXFORGE 描述为二氢吡啶类钙通道阻滞剂氨氯地平与血管紧张素 II 受体阻滞剂缬沙坦的固定复方。机制帮助理解为何完整药单核对重要，不预测个人血压、肾功能、血钾、疗效、用量或是否适合换药。", "en": "The current label describes EXFORGE as a fixed combination of the dihydropyridine calcium-channel blocker amlodipine and the angiotensin-II receptor blocker valsartan. Mechanism helps explain why complete-list review matters; it does not predict an individual's blood pressure, kidney function, potassium, response, amount or whether a switch is suitable." }, "checks": [ { "zh": "两个作用路径不表示可把其他钙通道阻滞剂、ARB、ACE 抑制剂或复方降压药自行再加一层。任何新增、停用、轮换或替代都要由掌握完整药单和病史的专业人员核对。", "en": "Two pathways do not mean another calcium-channel blocker, ARB, ACE inhibitor or combination antihypertensive can be self-added. Any addition, stopping, alternation or substitution needs review by a professional with the complete list and history." }, { "zh": "血管紧张素通路、血钾或肾功能等标签词是需要专业复核的线索，不是从家庭血压读数、症状或网络经验自行调整片数的依据。", "en": "Label terms involving the angiotensin pathway, potassium or kidney function are cues for professional review, not grounds to change tablet count from a home blood-pressure reading, symptoms or online experience." }, { "zh": "机制说明不能处理脱水、严重低血压样不适、胸痛、过敏、妊娠相关风险或复杂多药联用。出现急性或严重担忧时应优先使用当地医疗支持。", "en": "A mechanism explanation cannot manage dehydration, severe low-blood-pressure-like symptoms, chest pain, allergy, pregnancy-related risk or complex polypharmacy. With an acute or serious concern, prioritise local medical support." } ], "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Clinical Pharmacology；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "scope": "mechanism_literacy_only_no_individual_dosing_or_substitution" }, "pharmacovigilance": { "status": "official_routes_only_no_live_alert_inference", "reviewedAt": "2026-08-22", "identity": { "brand": "Exforge", "generic": "氨氯地平/缬沙坦", "dosageFormClass": "口服薄膜衣片：氨氯地平/缬沙坦 5/160、10/160、5/320、10/320 mg（当前美国标签所列）" }, "labelSource": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "productRoutes": [ { "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" }, "status": "product_level_public_record_verified", "authority": { "zh": "美国国家医学图书馆 DailyMed", "en": "U.S. National Library of Medicine DailyMed" }, "market": { "zh": "美国", "en": "United States" }, "recordType": { "zh": "公开药品标签", "en": "Public medicine label" }, "reviewedAt": "2026-08-20", "scope": { "zh": "已逐项核对本档案可公开访问的产品级来源入口。该核对不代表已完成所有国家或地区的实时警示检索，也不代表该药存在或不存在当前风险。", "en": "This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk." } } ], "recordRoute": { "status": "product_level_public_record_verified", "authority": { "zh": "美国国家医学图书馆 DailyMed", "en": "U.S. National Library of Medicine DailyMed" }, "market": { "zh": "美国", "en": "United States" }, "recordType": { "zh": "公开药品标签", "en": "Public medicine label" }, "reviewedAt": "2026-08-20", "scope": { "zh": "已逐项核对本档案可公开访问的产品级来源入口。该核对不代表已完成所有国家或地区的实时警示检索，也不代表该药存在或不存在当前风险。", "en": "This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk." } }, "channels": [ { "id": "china-nmpa-drug-evaluation-centre", "authority": "NMPA 药品评价中心", "market": { "zh": "中国大陆", "en": "Mainland China" }, "title": { "zh": "药物警戒快讯与安全警示", "en": "Drug-vigilance bulletins and safety notices" }, "purpose": { "zh": "国家药监局药品评价中心发布的药物警戒快讯、安全警示及药品不良反应监测相关原始入口；具体产品仍须按批准文号、剂型、规格、持有人和公告日期逐项核对。", "en": "Primary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item." }, "source": { "id": "src_05ff2860226564d4", "label": "国家药监局药品评价中心：药物警戒与安全警示入口", "url": "https://www.cdr-adr.org.cn/", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "CN", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "fda-drug-safety-communications", "authority": "FDA", "market": { "zh": "美国", "en": "United States" }, "title": { "zh": "药物安全通讯", "en": "Drug Safety Communications" }, "purpose": { "zh": "监管机构就重要新安全问题、标签变化或风险沟通发布的原始页面。", "en": "Primary FDA pages for important new safety issues, labelling changes and risk communications." }, "source": { "id": "src_9177df9e1825aa72", "label": "FDA：Drug Safety Communications", "url": "https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "fda-medwatch", "authority": "FDA MedWatch", "market": { "zh": "美国", "en": "United States" }, "title": { "zh": "安全信息与严重问题报告", "en": "Safety information and serious-problem reporting" }, "purpose": { "zh": "美国 MedWatch 的安全信息和报告入口；报告不等同于已证实因果关系。", "en": "U.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality." }, "source": { "id": "src_e4739cd55d27ab51", "label": "FDA：MedWatch 药品安全信息与不良事件报告计划", "url": "https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "adverse_event_reporting", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "ema-pharmacovigilance", "authority": "EMA", "market": { "zh": "欧盟/欧洲经济区", "en": "European Union / European Economic Area" }, "title": { "zh": "药物警戒概览与 EudraVigilance", "en": "Pharmacovigilance overview and EudraVigilance" }, "purpose": { "zh": "欧盟药物警戒、疑似不良反应报告和 PRAC 安全评估的官方入口。", "en": "Official EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment." }, "source": { "id": "src_2ad42a3deae747d1", "label": "EMA：Pharmacovigilance overview", "url": "https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "EU", "accessStatus": "public_access_confirmed", "accessMode": "javascript_or_cookie_controls", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "mhra-drug-safety-update", "authority": "MHRA", "market": { "zh": "英国", "en": "United Kingdom" }, "title": { "zh": "Drug Safety Update", "en": "Drug Safety Update" }, "purpose": { "zh": "英国 MHRA 面向专业人士和公众的药品安全更新原始发布页。", "en": "Primary UK MHRA medicine-safety updates for professionals and the public." }, "source": { "id": "src_23fdbe67abeafc63", "label": "MHRA：Drug Safety Update", "url": "https://www.gov.uk/drug-safety-update", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "UK", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "pmda-drug-safety", "authority": "PMDA", "market": { "zh": "日本", "en": "Japan" }, "title": { "zh": "药品安全信息", "en": "Medicine safety information" }, "purpose": { "zh": "日本 PMDA 药品安全信息的英文官方入口；具体产品仍应以日文产品页和现行文件复核。", "en": "PMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents." }, "source": { "id": "src_06d6be2880f12024", "label": "PMDA：Safety Information Regarding Drugs", "url": "https://www.pmda.go.jp/english/safety/info-services/drugs/0001.html", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "JP", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "mfds-drug-safety-letters", "authority": "MFDS", "market": { "zh": "韩国", "en": "Republic of Korea" }, "title": { "zh": "药品安全性书信", "en": "Medicine safety letters" }, "purpose": { "zh": "韩国 MFDS 发布的药品安全性书信原始索引。原文为韩文，须按涉及产品、剂型、市场和日期逐项阅读；它不自动适用于其他市场，也不构成对个人情况的结论。", "en": "MFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case." }, "source": { "id": "src_2d7f5018cd05eff4", "label": "MFDS：药品安全性书信（韩文原始资料）", "url": "https://www.mfds.go.kr/brd/m_545/list.do", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "KR", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "hsa-adverse-events", "authority": "HSA", "market": { "zh": "新加坡", "en": "Singapore" }, "title": { "zh": "不良反应报告与药物安全信息", "en": "Adverse-event reporting and medicine-safety information" }, "purpose": { "zh": "新加坡 HSA 面向公众的疑似不良反应报告、药物安全信息与本地监管入口；一份报告不等同于个体因果关系，具体产品仍须按新加坡注册状态、剂型、规格、日期和现行产品资料逐项核对。", "en": "HSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information." }, "source": { "id": "src_9240397d5a8574c1", "label": "HSA：Report adverse events", "url": "https://www.hsa.gov.sg/adverse-events/", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "adverse_event_reporting", "market": "SG", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "health-canada-medeffect-advisories", "authority": "Health Canada", "market": { "zh": "加拿大", "en": "Canada" }, "title": { "zh": "MedEffect 加拿大：建议、警告与召回", "en": "MedEffect Canada: advisories, warnings and recalls" }, "purpose": { "zh": "加拿大政府 Health Canada 的 MedEffect 公开入口，汇集药品及健康产品的建议、警告、召回、报告与安全信息；具体产品仍须按市场、剂型、规格、公告日期和批号逐项核对。", "en": "Health Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item." }, "source": { "id": "src_212ec921fa6634ad", "label": "Health Canada：MedEffect Canada 建议、警告与召回", "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/advisories-warnings-recalls.html", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "CA", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "tga-safety-alerts", "authority": "TGA", "market": { "zh": "澳大利亚", "en": "Australia" }, "title": { "zh": "药品安全警示", "en": "Medicine safety alerts" }, "purpose": { "zh": "澳大利亚 TGA 的药品安全警示、建议和监测信息原始发布页。", "en": "Primary Australian TGA safety alerts, advisories and monitoring information for therapeutic products." }, "source": { "id": "src_ffe6142814f88fac", "label": "TGA：Safety alerts", "url": "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "AU", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "swissmedic-pharmacovigilance", "authority": "Swissmedic", "market": { "zh": "瑞士", "en": "Switzerland" }, "title": { "zh": "药物警戒与不良反应报告", "en": "Pharmacovigilance and suspected adverse-reaction reporting" }, "purpose": { "zh": "瑞士 Swissmedic 的药物警戒、信号评估和疑似不良反应官方入口；报告或信号本身不等同于对个体因果关系的确认。", "en": "Official Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality." }, "source": { "id": "src_c854f813ce2671df", "label": "Swissmedic：Pharmacovigilance", "url": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/pharmacovigilance.html", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "adverse_event_reporting", "market": "CH", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "medsafe-safety-communications", "authority": "Medsafe", "market": { "zh": "新西兰", "en": "New Zealand" }, "title": { "zh": "药品安全通讯", "en": "Medicine safety communications" }, "purpose": { "zh": "新西兰 Medsafe 面向公众和专业人士的药品安全通讯与归档入口；旧公告可能已被现行产品资料更新。", "en": "New Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information." }, "source": { "id": "src_3510c1a523ec9769", "label": "Medsafe：Safety Communications", "url": "https://www.medsafe.govt.nz/safety/SafetyCommunications.asp", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "NZ", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "sahpra-safety-information", "authority": "SAHPRA", "market": { "zh": "南非", "en": "South Africa" }, "title": { "zh": "药物安全信息、警示与药物警戒", "en": "Medicine safety information, alerts and pharmacovigilance" }, "purpose": { "zh": "南非 SAHPRA 面向公众和专业人士的药物安全信息、警示与药物警戒入口；官方警示不等同于产品在所有情形下不安全，具体产品仍须按南非注册状态、剂型、规格、公告日期与现行资料逐项核对。", "en": "SAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information." }, "source": { "id": "src_25b0aaefee742163", "label": "SAHPRA：Safety Information Updates / Pharmacovigilance", "url": "https://www.sahpra.org.za/safety-information-and-updates/", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "ZA", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "who-medicine-safety-alerts", "authority": "WHO", "market": { "zh": "全球", "en": "Global" }, "title": { "zh": "药品与疫苗安全警示档案", "en": "Medicine and vaccine safety-alert archive" }, "purpose": { "zh": "WHO 的跨市场安全警示档案；每条历史警示必须按公告日期、涉及产品和市场单独阅读。", "en": "WHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market." }, "source": { "id": "src_9a7dc56ec34c7e1a", "label": "WHO：Safety alerts for medicines and vaccines", "url": "https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/safety-alerts", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "GLOBAL", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } }, { "id": "anvisa-pharmacovigilance", "authority": "Anvisa", "market": { "zh": "巴西", "en": "Brazil" }, "title": { "zh": "药物警戒、警示与 VigiMed", "en": "Pharmacovigilance, alerts and VigiMed" }, "purpose": { "zh": "巴西 Anvisa 的药物警戒原始入口，涵盖警示、药物警戒公告、风险沟通和 VigiMed 报告路径；具体产品仍须按巴西批准状态、剂型、规格和公告日期逐项核对。", "en": "Anvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item." }, "source": { "id": "src_5de362c12580111d", "label": "Anvisa：Farmacovigilância（药物警戒、警示与 VigiMed）", "url": "https://www.gov.br/anvisa/pt-br/assuntos/fiscalizacao-e-monitoramento/farmacovigilancia", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "official_safety_monitoring", "documentKind": "regulatory_safety_communication", "market": "BR", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-22", "reviewedAt": "2026-08-22" } } ], "notices": [], "boundary": { "zh": "本卡将逐药产品级来源与 15 个市场级官方警戒入口放在同一处核验；它不表示已完成该药在所有国家或地区的实时警示检索，也不表示该药存在新的安全警示、召回或风险结论。请先以品牌名、通用名、剂型、规格、所在市场和公告日期逐项匹配；不要仅因看到标题自行停药、换药、加量或减量。", "en": "This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline." }, "scope": "official_routes_only_no_live_alert_inference" }, "archive": { "summary": "DailyMed 当前 EXFORGE 标签将其列为氨氯地平和缬沙坦的固定剂量复方口服片，列有 5/160、10/160、5/320、10/320 mg 四种双成分标示。本页帮助核对品牌、两种成分、完整双数字、实际包装、标签版本和目标市场；不把任何一个数字变成个人片数、加减量、联合、换药或停药方案。", "history": "当前美国标签列示 Initial U.S. Approval: 2007，SPL v36 的 Effective/Updated 日期为 2026-02-17、DailyMed Published 日期为 2026-02-18。EXFORGE HCT 另含氢氯噻嗪，是另一种三成分产品；名称相近、同含氨氯地平或缬沙坦都不建立自行替代或叠加关系。", "sourceDocuments": [ { "id": "src_5b99fe84908369a0", "label": "DailyMed（NLM）：EXFORGE 氨氯地平/缬沙坦当前美国公开标签（Novartis；SPL v36）", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" } ], "applicationNumber": "NDA 021990", "approvalTimeline": [ { "date": "2007-06-20", "title": { "zh": "NDA 021990 原始申请批准", "en": "NDA 021990 original application approval" }, "detail": { "zh": "FDA Drugs@FDA 公开记录将 EXFORGE 的原始申请（ORIG 1）标为 2007-06-20 获批；该美国监管节点不建立其他市场的批准、供应或个人适用性。", "en": "The FDA Drugs@FDA public record lists EXFORGE original application (ORIG 1) as approved on 20 Jun 2007. This U.S. regulatory node does not establish approval, supply or individual suitability in another market." }, "source": { "id": "src_37676edf6d98c53b", "label": "FDA: EXFORGE NDA 021990 original approval letter (2007-06-20)", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/021990s000ltr.pdf", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "historical_public_record", "documentKind": "approval_record", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "direct_document", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" } }, { "date": "2007", "title": { "zh": "当前标签所列美国初始批准年份", "en": "Initial U.S. approval year listed in the current label" }, "detail": { "zh": "当前 EXFORGE 标签列示 Initial U.S. Approval: 2007；该年份不自动说明其他市场的产品状态。", "en": "The current EXFORGE label lists Initial U.S. Approval: 2007; it does not establish product status in another market." }, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed: current EXFORGE public label, SPL v36", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" } }, { "date": "2026-02-17", "title": { "zh": "当前 SPL v36 生效/更新日期", "en": "Current SPL v36 effective/updated date" }, "detail": { "zh": "DailyMed 当前标签的 Effective/Updated 日期为 2026-02-17；该日期与公开日期分开记录。", "en": "The current DailyMed label's effective/updated date is 17 Feb 2026; it remains separate from publication." }, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed: current EXFORGE public label, SPL v36", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" } }, { "date": "2026-02-18", "title": { "zh": "DailyMed 公开当前 SPL v36", "en": "DailyMed published current SPL v36" }, "detail": { "zh": "DailyMed 将当前 v36 的 Published Date 列为 2026-02-18；页面不把它解释成个人治疗建议。", "en": "DailyMed lists 18 Feb 2026 as the current v36 Published Date; this page does not interpret it as individual-treatment advice." }, "source": { "id": "src_5b99fe84908369a0", "label": "DailyMed: current EXFORGE public label, SPL v36", "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7&version=36", "audience": "public", "reviewStatus": "approved", "publish": true, "documentStatus": "publication_status_unresolved", "documentKind": "product_label", "market": "US", "accessStatus": "public_access_confirmed", "accessMode": "public_web_page", "accessVerifiedAt": "2026-08-20", "reviewedAt": "2026-08-20" } } ], "marketStatus": [ { "market": { "zh": "美国", "en": "United States" }, "status": { "zh": "已链接当前双成分标签与一个精确包装展示", "en": "Current two-ingredient label and one exact package panel linked" }, "detail": { "zh": "展示图只对应 5 mg/160 mg、NDC 0078-0488-15、30 片装；不据此建立实际在售、库存或其他规格状态。", "en": "The image corresponds only to the 5 mg/160 mg, NDC 0078-0488-15, 30-tablet panel; it does not establish actual marketing, stock or another-strength status." } }, { "market": { "zh": "中国大陆、欧盟、日本及其他市场", "en": "Mainland China, EU, Japan and other markets" }, "status": { "zh": "待逐项建立市场记录", "en": "Market record not established" }, "detail": { "zh": "不从美国标签推定当地商品名、批准、规格、供应、原研关系或可替代性。", "en": "No local trade name, approval, strength, supply, originator relationship or interchangeability is inferred from the U.S. label." } } ], "frequentlyAskedQuestions": [ { "question": { "zh": "5/160 mg 是不是只看其中一个数字即可？", "en": "Can 5/160 mg be read as just one of its two numbers?" }, "answer": { "zh": "不能。它表示这一准确复方片中氨氯地平和缬沙坦的两组标示量。页面不把它变成个人片数、调整或与单方药的换算。", "en": "No. It identifies the two labelled ingredient amounts in this exact fixed-combination tablet. The page does not turn it into an individual tablet count, adjustment or conversion to single-ingredient medicines." } }, { "question": { "zh": "EXFORGE 与 EXFORGE HCT 能否自行互换？", "en": "Can EXFORGE and EXFORGE HCT be self-switched?" }, "answer": { "zh": "不能。EXFORGE HCT 另含氢氯噻嗪，是三成分产品。相近品牌名不建立可自行互换关系；请带实际药盒和完整药单咨询药师或开方团队。", "en": "No. EXFORGE HCT additionally contains hydrochlorothiazide and is a three-ingredient product. Similar brand names do not establish self-interchangeability; take the actual packs and complete medicine list to a pharmacist or prescribing team." } } ], "relatedMedicineChecks": [], "relatedArticleSlugs": [ "medicine-label-for-everyday-questions", "dosage-forms-are-part-of-medicine-identity", "how-to-read-a-drug-label" ] }, "canonicalUrls": { "zh": "https://origindrug.com/drugs/exforge/", "en": "https://origindrug.com/en/drugs/exforge/" }, "limitations": [ "No originator, generic, interchangeability, availability, price, holder, strength or sale-eligibility conclusion is inferred beyond the linked source documents.", "Target-market current labels and official records must be checked separately." ] }